This is the begnning of the page content
Common Drug Review
The Common Drug Review (CDR) conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Québec).
Canada’s public drug plans differ in terms of the people whom they serve and the drugs that they cover, but all need answers to critical questions for each new drug.
- How does it compare with alternatives?
- Which patients will it benefit?
- Will it deliver value for money?
The CDR helps inform and support drug plan decisions by providing equal access to timely evidence-based information and expert advice.
